Appreciate the comments pgs. Regarding point #3, I think ARRY could have some degree of leverage themself as, provided the data agrees, there's the potential for 520+bortezomib combo instead of 520+carfilzomib.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.